Evidence map›Paper›PMID 42170327›Full record

ArticleJournal of human immunity2026

Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease.

Valentina Guarnieri, Jesmeen Maimaris, Sohilla Lotfy, Elizabeth Rivers, Stuart Adams, Kimberly Gilmour, Andrea Meinhardt, Arnold Awuah, Mercedes Selby, Daisy Shillingford and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Valentina GuarnieriInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0002-5578-7002
Jesmeen MaimarisInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0003-4169-8209
Sohilla LotfyDivision of Immunology, Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0009-0000-3688-4504
Elizabeth RiversImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0000-0001-5814-8014
Stuart AdamsSIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2650-2848
Kimberly GilmourInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0003-0285-3958
Andrea MeinhardtImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0000-0002-7464-0751
Arnold AwuahImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0009-0004-5166-5659
Mercedes SelbyImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0009-0003-9024-7727
Daisy ShillingfordSIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0002-7986-3986
Emma GravettSIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0005-0926-0575
Susanne Kricke OrszulikSIHMDS-Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-0791-2291
Waseem QasimInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0001-8353-4494
David GoldblattImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0000-0002-0769-5242
Helen BragginsImmunology Department, Great Ormond Street Hospital, London, UK.ORCID https://orcid.org/0000-0002-4006-8638
Robert ChiesaInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0001-9323-0259
Maaike KustersInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0001-7601-9822
Reem ElfekyInfection, Immunity, and Inflammation Department, Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre, London, UK.ORCID https://orcid.org/0000-0001-9382-150X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994-2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (

Identifiers

PMID42170327
PMCPMC13177677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.